# Safety and Efficacy Study of CF101 to Treat Psoriasis

> **NCT00428974** · PHASE2 · COMPLETED · sponsor: **Can-Fite BioPharma** · enrollment: 76 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** CF101 1mg
- **DRUG:** CF101 2mg
- **DRUG:** CF101 4mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00428974
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428974, "Safety and Efficacy Study of CF101 to Treat Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00428974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*